Curis LifesciencesNSE:CURIS 19 EBITDA Margin % is 18.94% as of Mar. 2026, which is 9% below its 10-year median of 20.74. GuruFocus rates NSE:CURIS with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 952 Drug Manufacturers companies, Curis Lifesciences ranks better than 65.76% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Curis Lifesciences's EBITDA for the
six
months ended in Mar. 2026 was ₹114.0 Mil. Curis Lifesciences's Revenue for the
six
months ended in Mar. 2026 was ₹601.6 Mil. Therefore, Curis Lifesciences's EBITDA margin for the quarter that ended in Mar. 2026 was 18.94%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Curis Lifesciences EBITDA Margin % Related Terms
Curis Lifesciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Curis Lifesciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences EBITDA Margin % Chart
Curis Lifesciences Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
11.97
24.47
22.53
18.94
Curis Lifesciences Semi-Annual Data
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
11.97
24.47
22.53
18.94
NSE:CURIS vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curis Lifesciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curis Lifesciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curis Lifesciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Curis Lifesciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curis Lifesciences (NSE:CURIS) has a EBITDA Margin % of 18.94% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Curis Lifesciences and its competitors. This is near median its historical median of 20.74. Over the past decade, Curis Lifesciences' EBITDA Margin % has ranged from 11.97 to 24.47. According to the industry distribution chart, Curis Lifesciences ranks #326 out of 952 companies in the Drug Manufacturers industry, placing it in the top 34.2%.
Is Curis Lifesciences' EBITDA Margin % too high?
Curis Lifesciences' current EBITDA Margin % of 18.94% is near median its 10-year median of 20.74. Over the past 10 years, this metric has ranged from a low of 11.97 to a high of 24.47. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Curis Lifesciences' value of 18.94% is 51.9% above this industry median. Based on the distribution chart, Curis Lifesciences ranks #326 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Curis Lifesciences has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Curis Lifesciences' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curis Lifesciences ranks #326 out of 952 companies for EBITDA Margin %. This puts Curis Lifesciences in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Curis Lifesciences' value of 18.94% is 51.9% above this benchmark. Historically, Curis Lifesciences' own EBITDA Margin % has ranged from 11.97 to 24.47 over the past decade. While the company's 10-year median is 20.74 vs. the industry median of 12.47, Curis Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curis Lifesciences's current EBITDA Margin % of 18.94% is 51.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Curis Lifesciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curis Lifesciences's current EBITDA Margin % is 18.94%, which is near median its own 10-year median of 20.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curis Lifesciences stock overvalued right now?
Curis Lifesciences (NSE:CURIS) has a current EBITDA Margin % of 18.94%. The current EBITDA Margin % is 18.94%, which is near median its 10-year median of 20.74 and 51.9% above the Drug Manufacturers industry median of 12.47. Curis Lifesciences' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Curis Lifesciences (NSE:CURIS), the current EBITDA Margin % is 18.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curis Lifesciences Ltd is in the business of manufacturing of pharmaceutical products. It specializes in the manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral liquid, and Sterile Ophthalmic Ointments. The company's business verticals are: Loan License manufacturing, Contract Manufacturing, and Direct Export. The company derives revenue from the sale of its pharmaceutical products.
19GF Score
Get the complete analysis for NSE:CURIS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CURIS has been successfully added to your 